Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Does VIVUS Need a Partner?

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

There's no doubt that the potential market for VIVUS' (Nasdaq: VVUS  ) obesity drug, Qsymia, is enormous. The Centers for Disease Control and Prevention says there are 78 million obese adults in the U.S. With such staggering numbers, it's safe to assume that every primary care physician in the country sees an obese patient every day.

But VIVUS isn't going after every patient. And I think that's probably the best strategy at this point. The company has rented a sales force of 150 sales reps, through contract sales organization PDI (Nasdaq: PDII  ) , which VIVUS thinks is sufficient to call upon 25,000 physicians.

Rather than target patients who are looking to lose weight for cosmetic reasons, VIVUS is promoting the medical benefits of losing weight: improved cardiovascular health, reduced risk of developing diabetes, etc. Those 25,000 doctors it's targeting understand that (or are poised to) because they either work at obesity centers or treat a lot of patients with underlying secondary conditions.

I like the strategy, at least for now.

A large pharma partner -- like rivals Arena Pharmaceuticals (Nasdaq: ARNA  ) and Orexigen Therapeutics (Nasdaq: OREX  )  both have -- could put more sales reps in front of more doctors, but I think it's unlikely to help at the initial launch. Given the history of side effects with obesity drugs -- Wyeth's Fen-Phen and Abbott Labs' (NYSE: ABT  ) Meridia -- primary care physicians are likely to take a wait-and-see attitude and are unlikely to jump in writing multiple prescriptions.

This isn't going to be a quick launch to blockbuster status in large part because there's no pressing need to treat the patients. Obesity is a lifelong disease that kills slowly; treating patients in a few months or a few years doesn't matter that much. More sales reps aren't going to change that.

If you're thinking long term and not quarter to quarter, VIVUS' goal should be to get those 25,000 doctors to try the drug in a few patients, getting them comfortable with the risk-benefit profile. Once they see the see the pounds coming off, more prescriptions will be written. At that point, VIVUS can strike a deal with a big pharma marketing partner and demand premium terms or, more likely, sell the company at a higher valuation than it's at right now.

More information about VIVUS' risks and potential can be found in the Fool's new premium research report. To get the full scoop on VIVUS' potential as an investment -- including reasons to buy, sell, and an in-depth analysis of the challenges it's facing -- click here now to learn more today.

Read/Post Comments (0) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2105159, ~/Articles/ArticleHandler.aspx, 10/24/2016 10:19:37 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,241.45 95.74 0.53%
S&P 500 2,151.52 10.36 0.48%
NASD 5,302.48 45.07 0.86%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/24/2016 9:55 AM
VVUS $1.10 Down +0.00 +0.00%
VIVUS CAPS Rating: **
ABT $40.63 Up +0.13 +0.32%
Abbott Laboratorie… CAPS Rating: *****
ARNA $1.59 Up +0.02 +1.27%
Arena Pharmaceutic… CAPS Rating: **
IDXG $0.15 Down -0.01 -6.33%
PDI CAPS Rating: No stars
OREX $2.83 Up +0.01 +0.38%
Orexigen Therapeut… CAPS Rating: *